# Effect of Co-medications on Rapamycin (Sirolimus)

0 = no effect expected; ↓ = decreased rapamycin exposure (induction); ↑ = increased exposure (inhibition); values are approximate fold-changes.

| Substance | Prior days | Together | Subsequent days | Notes |
|---|---|---|---|---|
| Baclofen | 0 | 0 | 0 | Renal elimination |
| Daridorexant | 0 | 0 | 0 | CYP3A4 substrate; no inhibition/induction |
| Dextromethorphan | 0 | 0 | 0 | CYP2D6/3A4 substrate; no clinical induction/inhibition |
| Domperidone | 0 | 0 | 0 | CYP3A4/P-gp substrate; no perpetrator role |
| Duloxetine | 0 | 0 | 0 | CYP1A2/2D6 substrate; no 3A4/P-gp effect |
| Lercanidipine | 0 | 0 | 0 | CYP3A4 substrate only; no perpetrator role |
| Levothyroxine | 0 | 0 | 0 | Absorption issue only; no CYP3A4 effect |
| Lorazepam | 0 | 0 | 0 | UGT substrate |
| Metamizole | ↓ (0.5–0.8×) | ↓ (0.5–0.8× Cmax;<br>0.4–0.7× AUC) | ↓ (persists up to a week) | CYP3A4 inducer;<br>↓ calcineurin inhibitor levels;<br>offset may take ~1 week |
| Modafinil | ↓ (0.7–0.9×) | ↓ (0.7–0.9× Cmax;<br>0.6–0.8× AUC) | ↓ (persists for days) | Moderate CYP3A4 inducer;<br>onset ≥3–5 days;<br>persists after stop |
| Nebivolol | 0 | 0 | 0 | CYP2D6 substrate |
| Paracetamol | 0 | 0 | 0 | UGT metabolism; no 3A4/P-gp effect |
| Pramipexole | 0 | 0 | 0 | Renal elimination |
| Prucalopride | 0 | 0 | 0 | Weak P-gp substrate; no meaningful effect |
| Rabeprazole | 0 | 0 | 0 | CYP2C19/non-enzymatic; minimal 3A4 effect |
| Sildenafil | 0 | 0 | 0 | CYP3A4 substrate only; no perpetrator role |
| Tizanidine | 0 | 0 | 0 | CYP1A2 substrate |
| Tramadol | 0 | 0 | 0 | CYP2D6 + 3A4 substrate; not perpetrator |
| Vortioxetine | 0 | 0 | 0 | CYP2D6 substrate; no 3A4/P-gp effect |
| Zolpidem | 0 | 0 | 0 | CYP3A4 substrate; no meaningful perpetrator effect |
| Zopiclone | 0 | 0 | 0 | CYP3A4 substrate; not a relevant perpetrator |